In this edition, durvalumab improves survival in limited-stage small cell lung cancer, most adults do not test homes for radon exposure and more. Read the full coverage here: Durvalumab improves survival in limited-stage small cell lung cancer Survey: Most adults do not test homes for radon exposure, unconcerned about risks FDA fast tracks investigational bispecific therapy for aggressive lung cancer Research shows complexity of shared decision-making about lung cancer screening Keytruda-Lynparza combination misses survival targets in phase 3 lung cancer trial References: Núñez E, et al. Ann Fam Med. 2024;doi:10.1370/afm.3081. Press Release Press Release. Press Release Press Release

Ver todos los episodios